- Poster presentation
- Open Access
Cost effectiveness of lumbar epidural steroid injections
© Carreon et al; licensee BioMed Central Ltd. 2014
- Published: 4 December 2014
- Back Pain
- Clinic Visit
- Policy Decision
- Quality Adjust Life Year
- Quality Adjust Life
Economic value is an important component of healthcare policy decision making. The primary currency for comparing the value of competing healthcare interventions is the Cost per Quality Adjusted Life Year (QALY) gained.
To determine cost/QALY gained for lumbar epidural steroid injections (LESI).
Patients who had an LESI between June 2012 and July 2013 and had EQ-5D scores available before and after LESIs were identified. Costs were calculated based on the Medicare Fee Schedule multiplied by the number of LESIs done between the two clinic visits. QALYs were calculated using the EQ-5D.
There were 257 patients (157 females, 100 males), mean age 60.0 years (21 to 88) years. Cost per LESI was $608, with most patients receiving 3 LESIs over one year (range 1 to 6). The mean QALY gained was -0.006. One hundred twenty-two patients (47%) had a gain in QALY (mean= 0.083) at a cost of $16,503 per QALY gained, 103 had a loss in QALY (mean = -0.112) and 32 had no gain in QALY. Ten of the 122 patients who improved, and 19 of the 135 patients that did not improve had medical comorbidities that precluded surgery. Of the 112 patients who improved without medical comorbidities, 31 (28%) subsequently had surgery. Of the 116 patients who did not improve and had no medical comorbidities, 45 (39%) subsequently had surgery. This proportion is statistically significantly different at p=0.05. Although the patients who had surgery even after improvement with LESI had a lower mean QALY gain (0.067) compared to those that did not have surgery (0.089), this was not statistically significant (p=0.260).
This study indicates that at LESI may not be a cost-effective intervention in patients with low back pain. For the 122 patients who improved, cost per QALY gained was acceptable at $16,503. However for the 135 patients with no gain or a loss in QALY, the economics are unreportable with a cost per QALY gained being theoretically infinite. Further studies are needed in order to identify specific patient populations that will benefit from LESI, as the economic viability of LESI requires improved patient selection.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.